Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Business / Sapu Nano expands Sapu003 clinical trials
Business clinical trial expansion

Sapu Nano expands Sapu003 clinical trials

Analysis based on 6 articles · First reported Jun 03, 2026 · Last updated Jun 08, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The expansion of Sapu Nano's Sapu003 clinical program into international territories, supported by Global Clinical Trials (GCT), is a positive development for the biotechnology and pharmaceutical sectors. This move could lead to increased market potential for Sapu003 and potentially benefit Oncotelic Therapeutics, which is associated with the Deciparticle platform.

Biotechnology Pharmaceuticals
Event Summary

Sapu Nano announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection), a proprietary intravenous formulation of everolimus. The program, which initially had an Australian clinical footprint, is now expanding into Europe and other international territories. Sapu Nano appointed Global Clinical Trials (GCT) as the lead contract research organization to support the international execution of Study SP-03-B101. This study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of Sapu003 in patients with advanced mTOR-sensitive solid tumors. Dr. Vương Triều, CEO of Sapu Nano, highlighted that this expansion and the appointment of GCT provide the necessary international infrastructure for continued clinical development, positioning Sapu003 for broader global evaluation and future registrational studies, while also expanding access for patients with advanced cancers. Oncotelic Therapeutics is also mentioned as being involved, with its Deciparticle platform technology being utilized for Sapu003.

Key Actions
100 Sapu Nano expanded clinical program
90 Sapu Nano appointed Global Clinical Trials
80 Global Clinical Trials completed regulatory submissions
Entities Involved
oth
Sapu Nano
Sapu Nano is expanding its Phase 1b clinical development program for Sapu003 and appointed Global Clinical Trials (GCT) as the lead CRO, which is a significant step towards global registrational studies and broader patient access.
Importance 100 Sentiment 70
oth
Global Clinical Trials
Global Clinical Trials (GCT) was appointed as the lead contract research organization for Sapu Nano's Sapu003 Phase 1b program, supporting its international expansion into Europe and other territories.
Importance 80 Sentiment 60
stock
Oncotelic Therapeutics
Oncotelic Therapeutics is involved in the expansion of the Sapu003 clinical development program, as Deciparticle, the platform technology used for Sapu003, is identified as Oncotelic's proprietary nanomedicine platform in one article.
Importance 70 Sentiment 50
cnt
Australia
The Sapu003 clinical program is expanding beyond its initial clinical footprint in Australia to other international territories.
Importance 20 Sentiment 0
loc
Europe
The SP-03-B101 study is expanding into Europe as part of its multinational development strategy.
Importance 20 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.